Siamab Therapeutics appoints Robert Mashal to board
This article was originally published in Scrip
Executive Summary
Newton, Massachusetts-based Siamab Therapeutics, a biotechnology company developing cancer immunotherapies, has appointed Dr Robert Mashal, current president and chief executive officer of NKT Therapeutics, to its board of directors. Before joining NKT Therapeutics, Dr Mashal was president of Alinea Pharmaceuticals.